U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H22FN3O2
Molecular Weight 379.4274
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BELAPERIDONE

SMILES

[H][C@]12C[C@H](C3=CC=C(F)C=C3)[C@@]1([H])CN(CCN4C(=O)NC5=C(C=CC=C5)C4=O)C2

InChI

InChIKey=XLJWJFKYRFPJSD-LZQZEXGQSA-N
InChI=1S/C22H22FN3O2/c23-16-7-5-14(6-8-16)18-11-15-12-25(13-19(15)18)9-10-26-21(27)17-3-1-2-4-20(17)24-22(26)28/h1-8,15,18-19H,9-13H2,(H,24,28)/t15-,18-,19+/m1/s1

HIDE SMILES / InChI

Description

Belaperidone (LU111995) is a recently identified antipsychotic agent with high 5-hydroxytryptamine2 and dopamine D4 receptor affinities as well as D4 versus D2 receptor selectivity. The drug did not produce catalepsy. LU111995 prolongs the Q-T interval to a limited degree and is not arrhythmogenic over the physiological range of cycle lengths. Belaperidone had been in phase II clinical trials for the treatment of schizophrenia. However, the study about this drug candidate was discontinued.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
3.1 nM [Ki]
3.3 nM [Ki]
105.0 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

T1/2

ValueDoseCo-administeredAnalytePopulation
12 h
unknown, oral
BELAPERIDONE plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
1.4%
unknown, oral
BELAPERIDONE plasma
Homo sapiens

Sourcing

PubMed

Sample Use Guides

In Vivo Use Guide
200 mg per day
Route of Administration: Oral
In Vitro Use Guide
There was no significant effect of LU111995 on maximum diastolic potentia at LU111995 concentrations up to 3 x 10(-6) M at any cycle length (e.g., at CL = 1000 ms, MDP = -91 mV in Purkinje fibers and -89 mV in mid myocardial cells at 3 x 10(-6) M, P>0.05 compared with control).